MarginsXMarginsX
Home › Markets › Health Care › PMCB

PharmaCyte Biotech Inc. (PMCB)

PMCB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.57
-16.62% on the day
Market cap
$59.8M
Micro cap
Revenue · 2026
$0
Prior year not contiguous
Net income · 2026
-$19.4M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-04-30, https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/0001683168-26-005836-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-04-30.

Profile

FieldValue
TickerPMCB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001157075
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNV

Financials · 2026

LineValue
Revenue$0
Net income-$19.4M
Operating income-$6.9M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$18.6M
Total assets$46.8M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
54.0 months
$17.7M cash at July 31, 2026
Share count, 1 year
+58.0%
2025-09-12 to 2026-09-11 · +22.3% over 3 years
Going-concern doubt
No
10-Q filed September 14, 2026
Insider net buying, 12 months
$129K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-09-14
Cash and burn$17.7M cash; operating cash flow -$985K a quarter.Report 2026-07-31
Shares outstandingNo cover-page share count in XBRLCover page 2026-09-11
Reverse splits, 3 years1; latest 1-for-19 on 2026-11-13Source 2026-11-13
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2025-12-05
AuditorCBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 2 times in 24 months8-K 4.01 2026-10-16
Late filings, 12 months1 NT noticeNT 10-Q 2025-12-15
Insider trades, 12 monthsBought $129K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-07-31
$0-$5.1M-$781K$17.7MNo debt tags$010-Q 2026-09-14
Q4 2026
2026-04-30
$0-$4.4M-$1.4M$18.6MNo debt tags$010-K 2026-07-29
Q3 2026
2026-01-31
$0$747K-$787K$20.2MNo debt tags$010-Q 2026-03-17
Q2 2026
2025-10-31
$0-$7.4M-$980K$15.4MNo debt tags$010-Q 2025-12-18
Q1 2026
2025-07-31
$0-$8.4M-$2.0M$13.2MNo debt tags$010-Q 2026-09-14
Q4 2025
2025-04-30
$0$11.7M-$1.0M$15.2MNo debt tags$010-K 2026-07-29
Q3 2025
2025-01-31
$0-$3.0M-$510K$16.4MNo debt tags$010-Q 2026-03-17
Q2 2025
2024-10-31
$0-$1.5M-$1.1M$20.8MNo debt tags$010-Q 2025-12-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32025-09-17
Latest annual report
FORM 10-K FOR APRIL 2026
10-K2026-07-29
Latest quarterly / interim
FORM 10-Q FOR JUL 2026
10-Q2026-09-14
Latest current report
CURRENT REPORT
8-K2026-11-13
Latest proxy
DEFINITIVE PROXY STATEMENT
DEF 14A2026-03-09

Source: SEC EDGAR submissions feed, 473 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.3%
1 month-1.2%
3 months-36.1%
Year to date-51.4%
1 year-55.5%
From 52-week high-71.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M
OKYOOKYO Pharma Limited$1.18-12.96%$61.7M
CSBRChampions Oncology Inc.$4.68-0.53%$65.1M
ATRAAtara Biotherapeutics Inc.$6.40-16.88%$65.2M
CRDFCardiff Oncology Inc.$0.8477+16.75%$65.9M
GRMLGreenland Mines Ltd.$3.50-3.05%$51.9M
NMRANeumora Therapeutics Inc.$0.3695-13.85%$69.4M
ELOXEloxx Pharmaceuticals Inc.$12.75-3.04%$51.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier